Viewing Study NCT03222492

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:48 PM
Ignite Modification Date: 2026-05-29 @ 12:55 AM
Study NCT ID: NCT03222492
Status: COMPLETED
Last Update Posted: 2024-05-17
First Post: 2017-07-17
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Brentuximab Vedotin for Systemic Sclerosis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Cutaneous Systemic Sclerosis View
None Scleroderma View
None dcSSc View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Diffuse Cutaneous Systemic Sclerosis (dcSSc) View
None Phase 1/2 clinical trial View
None dose escalation randomized trial View
None Brentuximab vedotin View